XBiotech Inc
4XB
Company Profile
Business description
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
Contact
5217 Winnebago Lane
AustinTX78744
USAT: +1 512 386-2900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
92
Stocks News & Analysis
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.
stocks
Why I dislike dividend stocks
If you need income then buying dividend stocks makes perfect sense. But if you don’t then it makes little sense because it’s likely to limit building real wealth. Here’s what you should do instead.
stocks
Chart of the Week: Ramsay Health Care margins to rebound
Charts from our latest stock pitch for Ramsay Health Care show a clear path to improved profitability.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,293.20 | 45.10 | -0.48% |
CAC 40 | 8,189.52 | 0.93 | 0.01% |
DAX 40 | 23,830.99 | 441.20 | -1.82% |
Dow JONES (US) | 46,190.61 | 238.37 | 0.52% |
FTSE 100 | 9,348.01 | 88.08 | -0.93% |
HKSE | 25,247.10 | 641.41 | -2.48% |
NASDAQ | 22,679.97 | 117.44 | 0.52% |
Nikkei 225 | 47,582.15 | 695.59 | -1.44% |
NZX 50 Index | 13,289.21 | 99.89 | -0.75% |
S&P 500 | 6,664.01 | 34.94 | 0.53% |
S&P/ASX 200 | 8,995.30 | 34.70 | -0.38% |
SSE Composite Index | 3,839.76 | 76.47 | -1.95% |